LLY

750.35

-0.93%↓

JNJ

151.92

+0.42%↑

UNH

311.9

+7.09%↑

ABBV

184.93

+0.53%↑

NVO

66.4

+3.2%↑

LLY

750.35

-0.93%↓

JNJ

151.92

+0.42%↑

UNH

311.9

+7.09%↑

ABBV

184.93

+0.53%↑

NVO

66.4

+3.2%↑

LLY

750.35

-0.93%↓

JNJ

151.92

+0.42%↑

UNH

311.9

+7.09%↑

ABBV

184.93

+0.53%↑

NVO

66.4

+3.2%↑

LLY

750.35

-0.93%↓

JNJ

151.92

+0.42%↑

UNH

311.9

+7.09%↑

ABBV

184.93

+0.53%↑

NVO

66.4

+3.2%↑

LLY

750.35

-0.93%↓

JNJ

151.92

+0.42%↑

UNH

311.9

+7.09%↑

ABBV

184.93

+0.53%↑

NVO

66.4

+3.2%↑

Search

Arcutis Biotherapeutics Inc

Abierto

SectorSalud

14.36 2.13

Resumen

Variación precio

24h

Actual

Mínimo

13.62

Máximo

14.36

Métricas clave

By Trading Economics

Ingresos

-14M

-25M

Ventas

-5.5M

66M

BPA

-0.2

Margen de beneficio

-38.059

Empleados

342

EBITDA

-20M

-25M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+35.65% upside

Dividendos

By Dow Jones

Próximas Ganancias

13 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-101M

1.7B

Apertura anterior

12.23

Cierre anterior

14.36

Noticias sobre sentimiento de mercado

By Acuity

72%

28%

347 / 382 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Arcutis Biotherapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

18 may 2025, 23:47 UTC

Charlas de Mercado

Nikkei May Trade Rangebound Amid Uncertainty Over U.S. Tariffs -- Market Talk

18 may 2025, 23:40 UTC

Charlas de Mercado

Gold Rises Amid Concerns Over U.S. Fiscal Deficit -- Market Talk

18 may 2025, 18:00 UTC

Ganancias

Tax Bill News; Target, Home Depot, and Snowflake Earnings; and More Stock Market News to Watch This Week -- Barrons.com

18 may 2025, 17:01 UTC

Principales Noticias

GM Is Fighting California on EVs. This Is What It Wants to Overturn and Why. -- Barrons.com

18 may 2025, 16:20 UTC

Ganancias

Tesla Demand Hasn't Rebounded Yet. Watch China This Week. -- Barrons.com

18 may 2025, 12:09 UTC

Principales Noticias

Trump Sounds Upbeat on Ukraine Cease-Fire as Russia Unleashes Drone Barrage -- WSJ

17 may 2025, 17:15 UTC

Principales Noticias

Trump Attacks Walmart for Tariff-Related Price Increases -- WSJ

17 may 2025, 09:30 UTC

Principales Noticias
Ganancias

In a Trade War, Walmart Lacks Some of Amazon's Ammunition -- Heard on the Street -- WSJ

17 may 2025, 08:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 may 2025, 08:20 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

16 may 2025, 23:18 UTC

Principales Noticias

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 may 2025, 22:30 UTC

Principales Noticias

U.S. Loses Last Triple-A Credit Rating -- Update

16 may 2025, 21:56 UTC

Charlas de Mercado

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 may 2025, 21:56 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 may 2025, 21:54 UTC

Principales Noticias

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 may 2025, 21:22 UTC

Charlas de Mercado

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 may 2025, 21:17 UTC

Charlas de Mercado

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 may 2025, 21:17 UTC

Principales Noticias

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 may 2025, 21:05 UTC

Charlas de Mercado

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 may 2025, 20:55 UTC

Adquisiciones, fusiones, absorciones

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 may 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

16 may 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

16 may 2025, 20:37 UTC

Principales Noticias

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 may 2025, 20:33 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 may 2025, 20:30 UTC

Adquisiciones, fusiones, absorciones

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 may 2025, 20:18 UTC

Principales Noticias

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 may 2025, 20:16 UTC

Principales Noticias

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 may 2025, 20:15 UTC

Ganancias

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 may 2025, 20:11 UTC

Adquisiciones, fusiones, absorciones

Henry Schein: William K. Daniel Joins Board

16 may 2025, 20:10 UTC

Adquisiciones, fusiones, absorciones

Henry Schein: Strategic Investment by KKR Completed

Comparación entre iguales

Cambio de precio

Arcutis Biotherapeutics Inc Esperado

Precio Objetivo

By TipRanks

35.65% repunte

Estimación a 12 meses

Media 19.14 USD  35.65%

Máximo 21 USD

Mínimo 15 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Arcutis Biotherapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

7

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

12.42 / 14.93Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

347 / 382 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.